(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Nurturing Hacks: Astuteness from Experienced Mothers and Fathers - 2Council removes proposal to rename park named after former president of Israel
- 3No red, no long shorts: The fashion rules Joe Burrows lives by
- 4Day to day Temporary Positions That Compensate Fairly in the US
- 5Tragedy in Minnesota, vaccine news, Snoop's game call: Week in review
- Top 20 Wellbeing and Wellness Applications for a Sound Way of life
- Vote in favor of your #1 Kind of Cap
- Woman shocked to welcome baby after experiencing stomach pain on Christmas
- Every year, she thanks the trooper for the arrest that led to her sobriety
- Excelling at Discussion: Genuine Examples of overcoming adversity
- Was This Driver Simply Having A great time Or Behaving Like An Ass?
- Is 'Veronica Mars' about to be your new binge-watch? It's now streaming on Netflix.
- 7 Methods for further developing Rest Quality
- Hezbollah rockets hit 165 UNIFIL positions in Lebanon while targeting Israel, IDF reveals
